Business
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) to Present at Wall Street Conference on May 21
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - May 21, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage bio...
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.","length":145,"tagName":"p"},{"type":"text","content":"LOS ANGELES, CA - May 21, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that Founder and CEO Dr. Jonathan Javitt will deliver a company update at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida. NRx is one of six companies invited to present at the high-profile event, which is expected to draw more than 1,000 attendees representing over $1 trillion in investment capital.","length":458,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"Investor Brand Network","className":"","disableSlideshowImg":false,"size":{"original":{"width":1400,"height":800,"url":"https://media.zenfs.com/en/newsmediawire_165/1404d3c7a527204db4bfbc5ec2f0d049"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o36PaSlK5Y87B75YqIrBaQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0OTtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/1404d3c7a527204db4bfbc5ec2f0d049","width":960,"height":549},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/.PjJX.VzQDrFNi3U4MSJrQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzcyO2NmPXdlYnA-/https://media.zenfs.com/en/newsmediawire_165/1404d3c7a527204db4bfbc5ec2f0d049","width":1200,"height":686}}},{"type":"text","content":"The presentation will highlight the company's progress toward FDA approval of NRX-100, a preservative-free intravenous ketamine formulation, as well as its strategic acquisition plans for HOPE clinics focused on treating suicidal depression, PTSD, and related conditions.","length":275,"tagName":"p"},{"type":"text","content":"To view the full press release, visit https://ibn.fm/eYj6T","length":58,"tagName":"p"},{"type":"text","content":"About NRx Pharmaceuticals, Inc.","length":31,"tagName":"p"},{"type":"text","content":"NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depre...